比较在传统治疗基础上加用多级椎体强化术是否会改善多发性骨髓瘤患者的预后。不过你提供的原文中“if”有误，应该是“of” 。

Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma.

作者信息

Audat Ziad A, Hajyousef Mahmoud H, Fawareh Mohammad D, Alawneh Khaldoon M, Odat Mohannad A, Barbarawi Mohammad M, Alomari Ali A, Jahmani Rami A, Khatatbeh Mohammad A, Assmairan Mohammed A

机构信息

Orthopedic Department, Jordan University of Science & Technology, King Abdullah University Hospital, Irbid, 22110 Jordan.

King Abdullah University Hospital, Amman-Ramtha Road, Irbid, 22110 Outside of the US Jordan.

出版信息

Scoliosis Spinal Disord. 2016 Dec 29;11:47. doi: 10.1186/s13013-016-0107-6. eCollection 2016.

BACKGROUND

This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients.

METHODS

We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS).

RESULTS

Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. -values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group).

CONCLUSION

Adding vertebral augmentation to conventional therapy improves multiple myeloma patients' quality of life, but didn't affect the mortality rate.

背景

这是一项前瞻性研究，旨在评估在多发性骨髓瘤患者中，除传统治疗外进行多级椎体强化的效果。

方法

我们治疗了27例通过两种治疗方式最近被诊断为多发性骨髓瘤的患者。13例患者（I组）接受传统治疗，14例患者（II组）接受椎体成形术和后凸成形术。在治疗前以及治疗后半年、1年、2年和3年，使用奥斯维斯特残疾指数（ODI）、斯坦福评分（SS）和脊柱不稳定肿瘤评分（SINS）对患者进行评估。

结果

治疗开始前，I组ODI、SS和SINS的平均值分别为31.9（63.8%）、4.3和13.8，II组分别为33.2（66.4%）、4.6和12.8。在所有随访期间，II组的改善情况均优于I组，在前6个月效果最佳。研究结束时的P值分别为ODI = 0.047、SS = 0.180和SINS = 0.002。两组的死亡率相同（每组4例患者）。